Arrowhead Pharmaceuticals (ARWR) shares have gained strong momentum over the past month, surging more than 20%. Investors are watching closely as the company continues to deliver healthy revenue growth and improved earnings compared to last year.

Arrowhead Pharmaceuticals has shown a remarkable turnaround, with the stock’s share price up more than 100% year-to-date and a staggering 151% gain over the past 90 days. That impressive run reflects renewed optimism about the company’s long-term prospects, especially considering its 1-year total shareholder return now sits just under 98%, far outpacing its modest performance over the past five years. With momentum clearly building, investors are watching closely to see if the good news can be sustained.

If biotech momentum is on your radar, this could be the moment to discover promising innovators with outstanding fundamentals. Start your search with our See the full list for free..

But after such a dramatic rally, the key question is whether Arrowhead Pharmaceuticals remains undervalued given its growth outlook, or if the market has already factored in all the good news. Could there still be a buying opportunity?

Most Popular Narrative: 16.7% Undervalued

Arrowhead Pharmaceuticals closed at $39.55, while the narrative-backed fair value estimate is $47.50. This narrative spotlight is propelled by the biotech’s rapid partnerships and innovation pipeline, and it offers a compelling rationale behind its premium valuation.

"Arrowhead's advancing late-stage clinical pipeline, especially the expected launch of plozasiran for FCS and SHTG, plus pivotal studies for three other RNAi therapies targeting major unmet needs, positions the company to capitalize on rising demand for innovative treatments that are driven by an aging population and increasing prevalence of chronic and genetic diseases. This could significantly accelerate revenue growth as approvals and launches materialize."

What is powering this ambitious price target? Dive in to decode the projections around novel drug launches, global partnerships, and blockbuster profit assumptions. See which critical valuation levers set Arrowhead apart. Are their growth assumptions bold, or does the math check out? The full narrative reveals the numbers and strategy behind the story.

Result: Fair Value of $47.50 (UNDERVALUED)

However, lingering risks remain, including heavy reliance on milestone payments and the possibility of regulatory delays that could disrupt Arrowhead’s optimistic growth trajectory.

Build Your Own Arrowhead Pharmaceuticals Narrative

If you want to dig into the numbers yourself or craft your own perspective, you can easily create a custom thesis in just a few minutes. Do it your way

A great starting point for your Arrowhead Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Don’t let opportunity pass you by. Use the Simply Wall Street Screener to find bold investments other investors might miss. These hand-picked ideas could be your next winning move.

• Tap into technology’s future and start tracking the innovators behind artificial intelligence by checking out these 26 AI penny stocks.
• Boost your portfolio with potential bargains and see which companies are primed for value right now using these 866 undervalued stocks based on cash flows.
• Step into the rapidly evolving world of decentralized finance and identify frontrunners with these 81 cryptocurrency and blockchain stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.